News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Idenix Pharmaceuticals, Inc. (IDIX)'s "Good" News Shows Hep C Drug Market Increasingly Murky For Investors


4/9/2014 6:05:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In the cutthroat hepatitis C drug market — the recent focus of a slew of biotechs, both big and small — investors seem to be increasingly unsure what constitutes good news.

Case in point is Idenix Pharmaceuticals (Nasdaq: IDIX), which saw its stock rise 12 percent over the course of the day yesterday after it reported “potent antiviral activity” for its lead drug for the disease. In a conference call with analysts yesterday, Chief Marketing Officer Douglas Meyers said that based on the results from its seven-day Phase 1/2 study of IDX21437 in 44 patients, the company is planning to start a Phase 2 trial of 200 to 300 hepatitis C patients

Help employers find you! Check out all the jobs and post your resume.


Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES